First human tests begin for new obesity and blood pressure drug
NCT ID NCT06148272
Summary
This is an early-stage study to check the safety and side effects of a new injectable drug called LY3971297. It will involve about 225 healthy adults and adults with obesity, high blood pressure, or reduced kidney function. The main goal is to see how the body handles the drug and what dose might be safe for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CenExel ACT
RECRUITINGAnaheim, California, 92801, United States
Contact Phone: •••-•••-••••
Contact
-
Clinical Pharmacology of Miami
NOT_YET_RECRUITINGMiami, Florida, 33172, United States
Contact Phone: •••-•••-••••
Contact
-
Clinical Research Hospital Tokyo
RECRUITINGShinjuku-ku, 160-0004, Japan
Contact Phone: •••-•••-••••
Contact
-
Hakata Clinic
RECRUITINGFukuoka, 812-0025, Japan
Contact Phone: •••-•••-••••
Contact
-
ICON Early Phase Services
RECRUITINGSan Antonio, Texas, 78209, United States
Contact Phone: •••-•••-••••
Contact
-
Lilly Centre for Clinical Pharmacology
RECRUITINGSingapore, 138623, Singapore
Contact Phone: •••-•••-••••
Contact
-
P-One Clinic
RECRUITINGHachiōji, 192-0071, Japan
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.